Skip to main content

ASCO GU 2018 Highlights

Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
By Phoebe Starr
Prostate Cancer, ASCO GU 2018 Highlights
April 2018, Vol 8, No 4
In 2 separate studies, apalutamide (Erleada) and enzalutamide (Xtandi) reduced the risk for metastasis and prolonged metastasis-­free survival in patients with nonmetastatic castrate-resistant prostate cancer (CRPC), according to the results of 2 clinical trials presented at the 2018 Genitourinary Cancers Symposium. Read More ›
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
By Phoebe Starr
Urothelial Cancer, ASCO GU 2018 Highlights
April 2018, Vol 8, No 4
Adjuvant chemotherapy had impressive gains in disease-free survival (DFS) and metastasis-free survival versus surveillance in upper-tract urothelial cancer (UTUC), according to the results of the phase 3 POUT clinical trial that were presented at the 2018 Genitourinary Cancers Symposium. Read More ›